{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:40:47Z","timestamp":1771850447073,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10147-024-02531-1","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T05:01:38Z","timestamp":1714453298000},"page":"863-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan"],"prefix":"10.1007","volume":"29","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"2531_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2024) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/files\/000252453.pdf Accessed on Mar 30, 2024"},{"key":"2531_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29:2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"key":"2531_CR3","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36:2684\u20132692. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112","journal-title":"J Clin Oncol"},{"key":"2531_CR4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284409","author":"E Pennesi","year":"2024","unstructured":"Pennesi E, Brivio E, Ammerlaan ACJ et al (2024) Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.284409","journal-title":"Haematologica"},{"key":"2531_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12185-022-03388-8","volume":"116","author":"H Nakayama","year":"2022","unstructured":"Nakayama H, Ogawa C, Sekimizu M et al (2022) A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed\/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). Int J Hematol 116:612\u2013621. https:\/\/doi.org\/10.1007\/s12185-022-03388-8","journal-title":"Int J Hematol"},{"key":"2531_CR6","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ et al (2023) Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 388:2058\u20132070. https:\/\/doi.org\/10.1056\/NEJMoa2214131","journal-title":"N Engl J Med"},{"key":"2531_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"2531_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"2531_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency (2024) Revision of PRECAUTIONS; Axicabtagene ciloleucel, Idecabtagene vicleucel, Tisagenlecleucel, Lisocabtagene maraleucel, https:\/\/www.pmda.go.jp\/files\/000267611.pdf Accessed on Apr 5, 2024"},{"key":"2531_CR10","unstructured":"Pharmaceuticals and Medical Devices Agency (2024) Summary of Investigation Results; Axicabtagene ciloleucel, Idecabtagene vicleucel, Tisagenlecleucel, Lisocabtagene maraleucel. https:\/\/www.pmda.go.jp\/files\/000267612.pdf Accessed on Apr 5, 2024"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02531-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:06:39Z","timestamp":1719223599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02531-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2531"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02531-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"30 April 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}